Download PDF
Geburtshilfe Frauenheilkd 2016; 76(12): 1310-1317
DOI: 10.1055/s-0042-116494
Review
GebFra Science
Georg Thieme Verlag KG Stuttgart · New York

Herpes Genitalis: Diagnosis, Treatment and Prevention

Diagnostik des Herpes genitalis, einschließlich antiviraler Therapie und prophylaktischer Möglichkeiten
A. Sauerbrei
Institut für Virologie und Antivirale Therapie, Konsiliarlabor für HSV und VZV, Universitätsklinikum Jena, Jena, Germany
› Author Affiliations
Further Information

Publication History

received 23 June 2016
revised 15 August 2016

accepted 01 September 2016

Publication Date:
18 October 2016 (online)

Also available at
   Permissions and Reprints

Abstract

Herpes genitalis is caused by the herpes simplex virus type 1 or type 2 and can manifest as primary or recurrent infection. It is one of the most common sexually transmitted infections and due to associated physical and psychological morbidity it constitutes a considerable, often underestimated medical problem. In addition to providing the reader with basic knowledge of the pathogen and clinical presentation of herpes genitalis, this review article discusses important aspects of the laboratory diagnostics, antiviral therapy and prophylaxis. The article is aimed at all health-care workers managing patients with herpes genitalis and attempts to improve the often suboptimal counselling, targeted use of laboratory diagnostics, treatment and preventive measures provided to patients.

Zusammenfassung

Der Herpes genitalis wird durch Herpes-simplex-Virus Typ 1 oder Typ 2 hervorgerufen und kann sich als primäre und rekurrierende Infektion manifestieren. Die Erkrankung gehört zu den häufigsten sexuell erworbenen Infektionskrankheiten und stellt aufgrund ihrer physikalischen und psychosozialen Morbidität ein erhebliches und oft unterschätztes medizinisches Problem dar. In der vorliegenden Übersichtsarbeit werden neben medizinischen Grundkenntnissen zum Erreger des Herpes genitalis und der Erkrankung wesentliche Aspekte der Labordiagnostik, einschließlich antivirale Therapie und prophylaktische Möglichkeiten vermittelt. Der Beitrag wendet sich an alle Mitarbeiter im Gesundheitsdienst, die Patienten mit Herpes genitalis betreuen, und zielt darauf ab, die häufig unzureichende Beratung sowie Maßnahmen bez. einer gezielten Diagnostik, Therapie und Prävention bei den betroffenen Patienten zu verbessern.

Key words

herpes simplex virus - herpes genitalis - laboratory diagnostics - antiviral therapy - prophylaxis

Schlüsselwörter

Herpes-simplex-Virus - Herpes genitalis - Labordiagnostik - antivirale Therapie - Prophylaxe

Supporting Information

 

  • References

  • 1 King AM, Adams MJ, Carstens EB, Lefcowitz EJ Hrsg. Virus Taxonomy. Ninth Report of the International Committee on Taxonomy of Viruses. San Diego, CA: Elsevier Academic Press; 2012: 99-124
    Google Scholar
  • 2 Bergström T, Trybala E. Antigenic differences between HSV-1 and HSV-2 glycoproteins and their importance for type-specific serology. Intervirology 1996; 39: 176-184
    CrossrefPubMedGoogle Scholar
  • 3 Scheper T, Saschenbrecker S, Steinhagen K et al. The glycoproteins C and G are equivalent target antigens for the determination of herpes simplex virus type 1-specific antibodies. J Virol Methods 2010; 166: 42-47
    CrossrefPubMedGoogle Scholar
  • 4 Sauerbrei A, Schmitt S, Scheper T et al. Seroprevalence of herpes simplex virus type 1 and type 2 in Thuringia, Germany, 1999 to 2006. Euro Surveill 2011; pii:20005
    PubMedGoogle Scholar
  • 5 Wutzler P, Doerr HW, Färber I et al. Seroprevalence of herpes simplex virus type 1 and type 2 in selected German populations-relevance for the incidence of genital herpes. J Med Virol 2000; 61: 201-207
    CrossrefPubMedGoogle Scholar
  • 6 Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002; 186 (Suppl. 01) S3-S28
    CrossrefPubMedGoogle Scholar
  • 7 Langenberg AG, Corey L, Ashley RL et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chirion HSV Vaccine Study Group. N Engl J Med 1999; 341: 1432-1438
    CrossrefPubMedGoogle Scholar
  • 8 Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003; 30: 797-800
    CrossrefPubMedGoogle Scholar
  • 9 Peña KC, Adelson ME, Mordechai E et al. Genital herpes simplex virus type 1 in women: detection in cervicovaginal specimens from gynecological practices in the United States. J Clin Microbiol 2010; 48: 150-153
    CrossrefPubMedGoogle Scholar
  • 10 Freeman EE, Weiss HA, Glynn JR et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20: 73-83
    CrossrefPubMedGoogle Scholar
  • 11 Bernstein DI, Bellamy AR, Hook 3rd EW et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis 2013; 56: 344-351
    CrossrefPubMedGoogle Scholar
  • 12 Corey L, Adams HG, Brown ZA et al. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983; 98: 958-972
    CrossrefPubMedGoogle Scholar
  • 13 Stevens JG, Cook ML. Latent herpes simplex virus in spinal ganglia of mice. Science 1971; 173: 843-845
    CrossrefPubMedGoogle Scholar
  • 14 Perna JJ, Mannix ML, Rooney JF et al. Reactivation of latent herpes simplex virus infection by ultraviolet light: a human model. J Am Acad Dermatol 1987; 17: 473-478
    CrossrefPubMedGoogle Scholar
  • 15 Rand KH, Hoon EF, Massey JK et al. Daily stress and recurrence of genital herpes. Arch Intern Med 1990; 150: 1889-1893
    CrossrefPubMedGoogle Scholar
  • 16 Bennedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994; 121: 847-854
    CrossrefPubMedGoogle Scholar
  • 17 Engelberg R, Carrell D, Krantz E et al. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis 2003; 30: 174-177
    CrossrefPubMedGoogle Scholar
  • 18 Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007; 370: 2127-2137
    CrossrefPubMedGoogle Scholar
  • 19 Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet 2001; 357: 1513-1518
    CrossrefPubMedGoogle Scholar
  • 20 Catotti DN, Clarke P, Catoe KE. Herpes revisited. Sex Transm Dis 1993; 20: 77-80
    CrossrefPubMedGoogle Scholar
  • 21 Hofstetter AM, Rosenthal L, Stanberry LR. Current thinking on herpes genitalis. Curr Opin Infect Dis 2014; 27: 75-83
    CrossrefPubMedGoogle Scholar
  • 22 Sauerbrei A. Herpes-simplex-Virusinfektionen. In: DVV, GfV, Hrsg. S2k-Leitlinie Labordiagnostik schwangerschaftsrelevanter Virusinfektionen. Berlin, Heidelberg: Springer; 2014: 145-157
    Google Scholar
  • 23 Anzivino E, Fioriti D, Mischitelli M et al. Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy and prevention. Virol J 2009; 6: 40
    CrossrefPubMedGoogle Scholar
  • 24 Sauerbrei A, Wutzler P. Herpes simplex and varicella-zoster virus infections during pregnancy – current concepts of prevention, diagnosis and therapy. Part 1: Herpes simplex virus infections. Med Microbiol Immunol 2007; 196: 89-94
    CrossrefPubMedGoogle Scholar
  • 25 Rudnick CM, Hoekzema GS. Neonatal herpes simplex virus infections. Am Fam Physician 2002; 6: 1138-1142
    PubMedGoogle Scholar
  • 26 Corey L, Wald A. Maternal and neonatal HSV infections. N Engl J Med 2009; 361: 1376-1385
    CrossrefPubMedGoogle Scholar
  • 27 Kohl S. Neonatal herpes simplex virus infection. Clin Perinatol 1997; 24: 129-150
    CrossrefPubMedGoogle Scholar
  • 28 Deutsche STI-Gesellschaft. S1-Leitlinie STI/STD – Beratung, Diagnostik und Therapie. Online: http://www.awmf.org/uploads/tx_szleitlinien/059-006l_S1_STI_STD-Beratung_2015-07.pdf last access: 22.06.2016
    PubMedGoogle Scholar
  • 29 Sauerbrei A, Eichhorn U, Hottenrott G et al. Virological diagnosis of herpes simplex encephalitis. J Clin Virol 2000; 17: 31-36
    CrossrefPubMedGoogle Scholar
  • 30 LeGoff J, Péré H, Bélec L. Diagnosis of genital herpes simplex virus infection in the clinical laboratory. Virol J 2014; 11: 83
    CrossrefPubMedGoogle Scholar
  • 31 Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64: 1-137
    CrossrefPubMedGoogle Scholar
  • 32 Patel R, Alderson S, Geretti A et al. European guideline for the management of genital herpes, 2010. Int J STD AIDS 2011; 22: 1-10
    CrossrefPubMedGoogle Scholar
  • 33 Wald A, Huang ML, Carrell D et al. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surface: comparison with HSV isolation in cell culture. J Infect Dis 2003; 188: 1345-1351
    CrossrefPubMedGoogle Scholar
  • 34 Sauerbrei A, Eichhorn U, Schacke M et al. Laboratory diagnosis of herpes zoster. J Clin Virol 1999; 14: 31-36
    CrossrefPubMedGoogle Scholar
  • 35 Wagenlehner FM, Brockmeyer NH, Discher T et al. The presentation, diagnosis and treatment of sexually transmitted infections. Dtsch Arztebl Int 2016; 113: 11-23
    PubMedGoogle Scholar
  • 36 Swiss Herpes Management Forum. Swiss recommendations for the management of genital herpes and herpes simplex virus infection of the neonate. Swiss Med Wkly 2004; 134: 205-214
    PubMedGoogle Scholar
  • 37 Brown ZA. Case study: type-specific HSV serology and the correct diagnosis of first-episode genital herpes during pregnancy. Herpes 2002; 9: 24-26
    PubMedGoogle Scholar
  • 38 Zahariadis G, Severini A. Evaluation of a novel serology algorithm to detect herpes simplex virus 1 or 2 antibodies. Sex Transm Dis 2010; 37: 696-699
    CrossrefPubMedGoogle Scholar
  • 39 Bentley J, Neubauer A, Sauerbrei A. Value of herpes simplex virus type-specific serology: a case report. J Clin Virol 2012; 54: 269-271
    CrossrefPubMedGoogle Scholar
  • 40 Hashido M, Inouye S, Kawana T. Differentiation of primary genital herpes infections by a herpes simplex virus-specific immunoglobulin G avidity assay. J Clin Microbiol 1997; 35: 1766-1768
    CrossrefPubMedGoogle Scholar
  • 41 Liermann K, Schäfler A, Henke A et al. Evaluation of commercial HSV IgG and IgM enzyme immunoassays. J Virol Methods 2014; 199: 29-34
    CrossrefPubMedGoogle Scholar
  • 42 Public Health Agency of Canada. Canadian guidelines on sexually transmitted infections. Section 5 – Management and treatment of specific infections. Genital herpes simplex virus (HSV) infections. Online: http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-5-4-eng.php last access: 11.08.2016
    PubMedGoogle Scholar
  • 43 German STI-Society. STI-Treatment Pocket Guide. Online: http://dstig.de/images/DSTIG-Flyer/Leitfaden/sti-treatment%2520pocket%2520guide_2014.2015_web.pdf last access: 22.06.2016
    PubMedGoogle Scholar
  • 44 De Clercq E. Selective anti-herpesvirus agents. Antivir Chem Chemother 2013; 23: 93-101
    CrossrefPubMedGoogle Scholar
  • 45 Le Cleach L, Trinquart L, Do G et al. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients (review). Cochrane Database Syst Rev 2014; (8) CD009036
    PubMedGoogle Scholar
  • 46 Hollier LM, Wendel D. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal herpes. Cochrane Database Syst Rev 2008; (1) CD004946
    PubMedGoogle Scholar
  • 47 Stone KM, Reiff-Eldridge R, White AD et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res Clin Mol Teratol 2004; 70: 201-207
    CrossrefPubMedGoogle Scholar
  • 48 Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 2010; 304: 859-866
    CrossrefPubMedGoogle Scholar
  • 49 Kang SH, Chua-Gocheco A, Einarson A. Safety of antiviral medication for the treatment of herpes during pregnancy. Can Fam Physician 2011; 57: 427-428
    PubMedGoogle Scholar
  • 50 Danve-Szatanek C, Aymard M, Thouvenot D et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004; 42: 242-249
    CrossrefPubMedGoogle Scholar
  • 51 Reyes M, Shaik NS, Graber JM et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003; 163: 76-80
    CrossrefPubMedGoogle Scholar
  • 52 Patel R, Green J, Clarke E et al. 2014 UK national guideline for the management of anogenital herpes. Int J STD AIDS 2015; 26: 763-776
    CrossrefPubMedGoogle Scholar
  • 53 Wald A, Corey L, Timmler B et al. Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med 2014; 370: 201-210
    CrossrefPubMedGoogle Scholar
  • 54 Collot M, Rouard C, Brunet C et al. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies. Antiviral Res 2016; 128: 1-6
    CrossrefPubMedGoogle Scholar
  • 55 Balfour jr. HH, Benson C, Braun J et al. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr 1994; 7: 254-260
    PubMedGoogle Scholar
  • 56 Sauerbrei A, Bohn-Wippert K, Kaspar M et al. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and 2. J Antimicrob Chemother 2016; 71: 6-16
    CrossrefPubMedGoogle Scholar
  • 57 Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003; 26: 29-37
    CrossrefPubMedGoogle Scholar
  • 58 Schmidt S, Bohn-Wippert K, Zell R et al. Sequence analysis of herpes simplex virus type 1 thymidine kinase and DNA polymerase genes from over 300 clinical isolates from 1973–2014 finds novel mutations which may be relevant for development of antiviral resistance. Antimicrob Agents Chemother 2015; 59: 4938-4945
    CrossrefPubMedGoogle Scholar
  • 59 Safrin S, Crumpacker C, Chatis P et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991; 325: 551-555
    CrossrefPubMedGoogle Scholar
  • 60 Awasthi S, Friedman M. Status of prophylactic and therapeutic genital herpes vaccines. Curr Opin Virol 2014; 6: 6-12
    CrossrefPubMedGoogle Scholar
  • 61 Odegard JM, Flynn PA, Campbell DJ et al. A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs. Vaccine 2016; 34: 101-109
    CrossrefPubMedGoogle Scholar
  • 62 Straus SE, Corey L, Burke RL et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994; 343: 1460-1463
    CrossrefPubMedGoogle Scholar
  • 63 Straus SE, Wald A, Kost RK et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoprotein D and B. results of a placebo-controlled vaccine trial. J Infect Dis 1997; 176: 1129-1134
    CrossrefPubMedGoogle Scholar
  • 64 Casanova G, Cancela R, Alonzo L et al. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. Cutis 2002; 70: 235-239
    PubMedGoogle Scholar
  • 65 deBruyn G, Vargas-Cortez M, Warren T et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 2006; 24: 914-920
    CrossrefPubMedGoogle Scholar
  • 66 Halford WP, Geltz J, Messer RJ et al. Antibodies are required for complete vaccine-induced protection against herpes simplex virus 2. PLoS One 2015; 10: e0145228
    CrossrefPubMedGoogle Scholar
  • 67 Stanaway JD, Wald A, Martin ET et al. Case-crossover analysis of condom use and herpes simplex virus type 2 acquisition. Sex Transm Dis 2012; 39: 388-393
    CrossrefPubMedGoogle Scholar
  • 68 Gottlieb SL, Douglas jr. JM, Foster M et al. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counselling. J Infect Dis 2004; 15: 1059-1067
    PubMedGoogle Scholar
  • 69 Abdool Karim SS, Abdool Karim Q, Kharsany AB et al. Tenofovir gel for the prevention of herpes simplex virus type 2 infection. N Engl J Med 2015; 373: 530-539
    CrossrefPubMedGoogle Scholar
  • 70 Bender Ignacio RA, Perti T, Magaret AS et al. Oral and vaginal tenofovir for genital herpes simplex virus type 2 shedding in immunocompetent women: a double-blind, randomized, cross-over trial. J Infect Dis 2015; 212: 1949-1956
    CrossrefPubMedGoogle Scholar
  • 71 Price CF, Tyssen D, Sonza S et al. SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS One 2011; 6: e24095
    CrossrefPubMedGoogle Scholar